Compare · BTI vs DFTX
BTI vs DFTX
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $127.80B, about 26.8x DFTX ($4.76B).
- Over the past year, BTI is up 14.8% and DFTX is up 424.0% - DFTX leads by 409.2 points.
- DFTX has been more active in the news (27 items in the past 4 weeks vs 4 for BTI).
- BTI has more recent analyst coverage (14 ratings vs 5 for DFTX).
PerformanceBTI+14.84%DFTX+424.01%
2025-07-14+0.00%2026-07-13
- Company
- British American Tobacco Industries p.l.c.
- Definium Therapeutics Inc.
- Price
- $58.97-1.73%
- $43.65-7.32%
- Market cap
- $127.80B
- $4.76B
- 1M return
- -3.53%
- +87.82%
- 1Y return
- +14.84%
- +424.01%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 4
- 27
- Recent ratings
- 14
- 5
BTI
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 11-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest DFTX
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)
- A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
- Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares